Haowei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haowei Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aiwu Li
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
2 shared publications - Chao Zhao
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai 200433, China
2 shared publications - Jun Xu
Stem Cell Research Center, School of Medicine, East Hospital, Tongji University, Shanghai, China
2 shared publications - Lei Cheng
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
2 shared publications - Xuefei Li
Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications Danlei Yu
Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China, tongji.edu.cn
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 8885469
Integrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma
Chemotherapy resistance is the primary barrier to improving survival in osteosarcoma (OS), yet reliable predictive biomarkers remain limited. Here, we developed and validated a 13‐gene signature via weighted gene coexpression network analysis (WGCNA) of chemotherapy‐resistant and sensitive OS transcriptomes. The risk model demonstrated robust prognostic value across four independent cohorts (TARGET‐OS, GSE21257, GSE16091, and GSE39055). Multiscale analysis revealed that high‐risk tumors exhibit proliferative hyperactivation, genomic instability with elevated TMB, and a paradoxical immune‐cold phenotype despite the high mutational load. Single‐cell and spatial transcriptomics demonstrated that high‐risk malignant cells display dedifferentiated, stem‐like properties, preferentially localize to hypoxic necrotic peripheries, and engage in extensive tumor–stromal crosstalk. Drug sensitivity predictions confirmed resistance to first‐line chemotherapy agents. Collectively, these findings establish a clinically actionable 13‐gene biomarker and provide a mechanistic framework linking transcriptional profiles to chemoresistance biology, exposing novel therapeutic vulnerabilities in OS.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 8885469
Open AccessIntegrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma
Chemotherapy resistance is the primary barrier to improving survival in osteosarcoma (OS), yet reliable predictive biomarkers remain limited. Here, we developed and validated a 13‐gene signature via weighted gene coexpression network analysis (WGCNA) of chemotherapy‐resistant and sensitive OS transcriptomes. The risk model demonstrated robust prognostic value across four independent cohorts (TARGET‐OS, GSE21257, GSE16091, and GSE39055). Multiscale analysis revealed that high‐risk tumors exhibit proliferative hyperactivation, genomic instability with elevated TMB, and a paradoxical immune‐cold phenotype despite the high mutational load. Single‐cell and spatial transcriptomics demonstrated that high‐risk malignant cells display dedifferentiated, stem‐like properties, preferentially localize to hypoxic necrotic peripheries, and engage in extensive tumor–stromal crosstalk. Drug sensitivity predictions confirmed resistance to first‐line chemotherapy agents. Collectively, these findings establish a clinically actionable 13‐gene biomarker and provide a mechanistic framework linking transcriptional profiles to chemoresistance biology, exposing novel therapeutic vulnerabilities in OS.
- Open Access
- 15 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 482
EGFR-Mutant Lung Adenocarcinoma Cell-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy; however, it was significantly lower in EGFR-mutant than wild type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomirs on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR-mutant lung adenocarcinoma cell-derived exosomes, which could promote CD8+ T cell apoptosis, while the miR-651-5p inhibitor decreased the ratio of PC9-secreted exosomes and induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor Fos proto-oncogene (FOS) in EGFR-mutant lung adenocarcinoma cell lines. B-cell lymphoma 2 (BCL2) was the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. In addition, the miR-651-5p antagomir increased T cell infiltration and enhanced the efficacy of the PD-1 inhibitor treating the EGFR-mutant lung adenocarcinoma humanized mouse model. Conclusions: EGFR-mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a new combination therapy to improve the efficacy of immunotherapy in EGFR-mutant NSCLC patients.
- 15 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 482
Open AccessEGFR-Mutant Lung Adenocarcinoma Cell-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy; however, it was significantly lower in EGFR-mutant than wild type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomirs on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR-mutant lung adenocarcinoma cell-derived exosomes, which could promote CD8+ T cell apoptosis, while the miR-651-5p inhibitor decreased the ratio of PC9-secreted exosomes and induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor Fos proto-oncogene (FOS) in EGFR-mutant lung adenocarcinoma cell lines. B-cell lymphoma 2 (BCL2) was the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. In addition, the miR-651-5p antagomir increased T cell infiltration and enhanced the efficacy of the PD-1 inhibitor treating the EGFR-mutant lung adenocarcinoma humanized mouse model. Conclusions: EGFR-mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a new combination therapy to improve the efficacy of immunotherapy in EGFR-mutant NSCLC patients.
- Open Access
- 23 December 2024
- Published by MDPI AG in Preprints.org
EGFR Mutant Lung Adenocarcinoma Cells-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy, however, it was significantly lower in EGFR mutant than wild-type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomir on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR mutant lung adenocarcinoma cell-derived exosomes which could promote CD8+ T cell apoptosis, while miR-651-5p inhibitor decreased the ratio of PC9 secreted exosomes induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor FOS in EGFR-mutant lung adenocarcinoma cell lines. BCL2 was identified as the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. Besides, miR-651-5p antagomir increased T cells infiltration and enhanced the efficacy of PD-1 inhibitor treating EGFR mutant lung adenocarcinoma in a humanized mouse model. Conclusions: EGFR mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a potential mechanism to improve the efficacy of immunotherapy in this group.
- 23 December 2024
- Published by MDPI AG in Preprints.org
Open AccessEGFR Mutant Lung Adenocarcinoma Cells-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression
Background: The efficacy of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) inhibitors in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients is not satisfactory. Studies have indicated that the ratio of CD8+ tumor infiltration lymphocytes (TILs) was associated with immunotherapy efficacy, however, it was significantly lower in EGFR mutant than wild-type patients. The underlying mechanisms need to be studied. Methods: Database analysis, clinical specimens, small RNA sequencing, and single-cell sequencing were used to analyze miRNA expression and immune cell infiltration. Cell co-culture and flow cytometry were conducted to detect immune cell apoptosis. The mouse model was performed to analyze the influence of miR-651-5p antagomir on the tumor microenvironment. Results: The miR-651-5p was found to be highly expressed in EGFR mutant lung adenocarcinoma cell-derived exosomes which could promote CD8+ T cell apoptosis, while miR-651-5p inhibitor decreased the ratio of PC9 secreted exosomes induced apoptosis. Mechanistically, the EGFR signaling pathway promoted the expression of miR-651-5p by activating the transcription factor FOS in EGFR-mutant lung adenocarcinoma cell lines. BCL2 was identified as the target of miR-651-5p, and miR-651-5p could promote T cell apoptosis by inhibiting BCL2 expression. Besides, miR-651-5p antagomir increased T cells infiltration and enhanced the efficacy of PD-1 inhibitor treating EGFR mutant lung adenocarcinoma in a humanized mouse model. Conclusions: EGFR mutant lung adenocarcinoma promotes T cell apoptosis through exosomal miR-651-5p. miR-651-5p antagonists increase immune cell infiltration and enhance the anti-tumor effect of PD-1 inhibitor, suggesting a potential mechanism to improve the efficacy of immunotherapy in this group.